Coya Therapeutics promotes Arun Swaminathan to CEO post

22 August 2024

Texas, USA-based Coya Therapeutics (Nasdaq: COYA)announced that Arun Swaminathan has been promoted to the role of chief executive (CEO) effective November 1, 2024.

He will succeed Dr Howard Berman who will continue to serve in the capacity of executive chairman.

Coya notes that, as it looks forward to and prepare for the release of Alzheimer's data at the upcoming CTAD24 conference on October 29, in Madrid and continue to progress COYA 302 in ALS, the company will benefit from leveraging Dr Swaminathan’s strategic, business development, operational, and deal making experience to guide Coya through its next phase in the company’s growth.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK